Pharma Focus Asia

Biosyngen Opens New Cell Therapy GMP Facility in Singapore

Friday, June 30, 2023

Biosyngen has announced the opening of its latest Good Manufacturing Practise (GMP) facility in Singapore. 

The opening of this GMP facility in Singapore represents a significant advancement in the country's capabilities in the field of cell manufacturing and R&D, particularly within the CGT industry.

This facility will serve as a hub for research and development in drug discovery and process development. It is also designed to accommodate advanced processes and products that may be introduced in the future.

The newly established facility is the first and largest privately owned fully automatic and enclosed integrated GMP cell manufacturing facility and R&D base in Singapore to date. It is compliant with the latest recommendations of the U.S. Food and Drug Administration (FDA), ensuring adherence to high standards. The facility enables Biosyngen to run automatic and closed-system production, which is considered the preferred best practise in the CGT industry.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024